Clinical Trial Results

Showing: All studies [change]
Condition: Breast Cancer Location: South Carolina 25 trials found
New Search
Filter
Trial Phase
Study Type
Hypoglossal Acupuncture for Dysgeusia in Patients Undergoing Chemotherapy
NAINTERVENTIONAL Essen, North Rhine-Westphalia +2 more
RECRUITING
Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)
PHASE3INTERVENTIONAL Tucson, Arizona +4 more
RECRUITING
Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects
PHASE3INTERVENTIONAL Mobile, Alabama +4 more
RECRUITING
Neoadjuvant Endocrine Therapy +/- the PI3K Inhibitor Inavolisib in HER2+, HR+, PIK3CA Mutant Early Breast Cancer
PHASE2INTERVENTIONAL Essen, North Rhine-Westphalia +4 more
RECRUITING
IMA402 T Cell-Engaging Receptor Molecule (TCER®) in Recurrent and/or Refractory Solid Tumors
PHASE1, PHASE2INTERVENTIONAL Heidelberg, Baden-Wurttemberg +4 more
RECRUITING
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
PHASE1, PHASE2INTERVENTIONAL Cerritos, California +4 more
RECRUITING
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
PHASE3INTERVENTIONAL Daphne, Alabama +4 more
RECRUITING
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
PHASE3INTERVENTIONAL Gilbert, Arizona +4 more
RECRUITING
Chemotherapy De-escalation in HR +, HER2-, Intermediate-risk Early Breast Cancer Treated With Adjuvant Ribociclib
PHASE3INTERVENTIONAL Amiens +4 more
RECRUITING
Marker - Adjusted Therapy Comparing Adjuvant Elacestrant With Standard Endocrine Treatment in Genomically and/or Clinically High-risk ER+/HER2- eBC
PHASE3INTERVENTIONAL Mannheim, Baden-Wurttemberg +4 more
RECRUITING
Role of Sodium-glucose Linked Transporter 2 (SGLT2) and Its Inhibitor Over CARdiotoxicity Induced by Anthracyclines and Breast Cancer Tumorigenesis SCARA-B
N/AOBSERVATIONAL Strasbourg
RECRUITING
Arm Swelling Occurence in Breast Cancer Patients With Nodal Radiotherapy: Impact of Informing Them of AI-predicted Risk
NAINTERVENTIONAL Arras +4 more
RECRUITING
ECLECTIC: EstroTEP and Circulating Biomarkers for ER-positive HER2-negative Metastatic Breast Cancer Patients
PHASE3INTERVENTIONAL Bayonne +4 more
RECRUITING
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer
PHASE3INTERVENTIONAL Phoenix, Arizona +4 more
RECRUITING
Effects Of Concentric Cycling Training Protocol During (Neo)Adjuvant Chemotherapy in Breast Cancer Patients: PROTECT-07 Study
NAINTERVENTIONAL Colmar +1 more
RECRUITING
Study Aiming to Compare the Plasma Exposure of the Payload (Free-DXd) in Patients Treated by T-DXd for Locally Advanced or Metastatic Breast Cancer According to Their BMI.
PHASE4INTERVENTIONAL Angers +4 more
RECRUITING
Capecitabine Plus Pembrolizumab in Patients With Triple Negative Breast Cancer After Chemo-immunotherapy and Surgery
PHASE2INTERVENTIONAL Amiens +4 more
RECRUITING
Capecitabine, Tucatinib, and Intrathecal Trastuzumab for Breast Cancer Patients With Leptomeningeal Disease
PHASE2INTERVENTIONAL Bordeaux +4 more
RECRUITING
TTV-based mAnagement Of Long-term ImmunosuppreSsion in Kidney Transplantation
NAINTERVENTIONAL Bordeaux (France) +3 more
RECRUITING
First-in-human, Study of MATTISSE® Tissue Engineering Chamber in Adult Female Patients Undergoing Breast Reconstruction After Mastectomy for Cancer
NAINTERVENTIONAL Strasbourg, France +2 more
RECRUITING
A Study of LOXO-783 in Patients With Breast Cancer/Other Solid Tumors
PHASE1INTERVENTIONAL Scottsdale, Arizona +4 more
RECRUITING
Identification of Genetic Determinants for Treatment Resistance/Sensitivity and/or Toxicity in Adjuvant Setting for HER2 Positive Breast Cancer
N/AOBSERVATIONAL Strasbourg
RECRUITING
Skipping Hormone Therapy in Low-Risk Early Breast Cancer
PHASE2INTERVENTIONAL Angers +4 more
RECRUITING
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
PHASE1, PHASE2INTERVENTIONAL Irvine, California +4 more
RECRUITING
Optimising Adjuvant Chemotherapy Prescription in Young Patients With Hormone-dependent Breast Cancer Using Genomic Tests
PHASE3INTERVENTIONAL Brussels +4 more
RECRUITING
Filter Trials
Trial Phase
Study Type